
28/05/2025
⚠TGA APPROVED⚠
A new therapy using the drug Kisunla (Donanemab) to reduce amyloid in the brain has been approved by the TGA in Australia.
Clinical trials for this drug have been conducted at ECRU since 2024 to assess safety and efficacy. With the drug now approved, individuals with early Alzheimer's disease can access this from July under strict clinical review. While the drug is costly, it will be reviewed in the coming months by an advisory committee for listing on the PBS.
Stay tuned for more details as infusion sites roll out across Melbourne.
Read more below 👇
The TGA has approved a drug found to slow the cognitive decline associated with Alzheimer's disease but it will only be available for a select few who can afford it privately.